Allogene Therapeutics Stock Price, News & Analysis

Allogene Therapeutics, a clinical-stage biotechnology company based in South San Francisco, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 12:40 p.m. Pacific Time. David Chang, M.D., Ph.D., the company's President and CEO, will lead the presentation. A live webcast will be available on Allogene's website with a replay accessible for 30 days. The company focuses on developing allogeneic CAR T therapies, aiming to provide readily available cancer treatments at scale.

Allogene Therapeutics (Nasdaq: ALLO) has announced that the FDA has approved its IND application to study ALLO-715 in combination with nirogacestat for multiple myeloma patients. This Phase 1 clinical trial, part of Allogene's strategy to target BCMA, is expected to begin enrollment in Q1 2021. The combination aims to enhance the effectiveness of ALLO-715 by preventing BCMA cleavage, potentially leading to improved patient responses. The collaboration with SpringWorks Therapeutics is pivotal for this study, with Allogene assuming development costs.

Allogene Therapeutics and Overland Pharmaceuticals have formed a joint venture called Allogene Overland Biopharm to develop AlloCAR T™ therapies for hematologic malignancies and solid tumors in Greater China, Taiwan, South Korea, and Singapore. Overland will invest $117 million, including a $40 million upfront payment. The venture aims to accelerate the availability of these therapies in Asia, with Allogene providing technical expertise and Overland offering operational support. Allogene retains global rights for their investigational candidates and will receive milestone payments upon regulatory approvals.

Allogene Therapeutics (Nasdaq: ALLO) announced significant preclinical findings for its investigational drug ALLO-605, a next-generation CAR T therapy targeting multiple myeloma. The results indicate that ALLO-605 exhibited enhanced killing of myeloma cells and greater persistence compared to traditional BCMA CAR T therapies. The company plans to file an Investigational New Drug (IND) application for ALLO-605 in the first half of 2021. TurboCAR technology, used in ALLO-605, aims to improve the efficacy of CAR T therapies by enhancing T cell activity and proliferation.

Allogene Therapeutics has announced promising preclinical results for ALLO-316, an AlloCAR T™ therapy targeting CD70, effective against leukemic cells in acute myeloid leukemia (AML). The U.S. FDA has cleared an Investigational New Drug (IND) application for ALLO-316, with a Phase 1 trial in renal cell carcinoma (RCC) set to start in 2021. These findings suggest ALLO-316's potential in treating both hematologic malignancies and solid tumors, reinforcing the importance of CD70 as a target across various cancers.

Allogene Therapeutics has announced promising data from the Phase 1 UNIVERSAL study of ALLO-715 for relapsed/refractory multiple myeloma. As of October 30, 2020, the study involved 35 patients, with 31 evaluable for safety and 26 for efficacy. The study reported a 60% overall response rate and a 40% very good partial response rate, with no instances of graft-versus-host disease or severe neurotoxicity observed. The data highlight the potential of ALLO-715 as an effective off-the-shelf therapy with fast treatment initiation, supporting its continued development and trials in the future.

Allogene Therapeutics (ALLO) is set to review initial results from the ALLO-715 UNIVERSAL Phase 1 trial targeting relapsed/refractory multiple myeloma in a live webinar scheduled for December 5, 2020, at 11:00 AM PT/2:00 PM ET. The webinar will feature key executives including CEO David Chang and CMO Rafael Amado. This clinical-stage biotechnology firm focuses on developing allogeneic CAR T therapies, aiming to provide scalable, readily available cancer treatments. Registration for the webinar is available on the company's website.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced its participation in four upcoming investor conferences, aiming to enhance investor relations. The conferences include the Stifel 2020 Virtual Healthcare Conference on November 16, Jefferies Virtual London Healthcare Conference on November 17, Piper Sandler’s 32nd Annual Virtual Healthcare Conference on December 2, and the JMP Securities Hematology Summit on December 15. Presentations will be webcasted and available on the company's website for 30 days post-event, promoting transparency and engagement with stakeholders.

Allogene Therapeutics announced promising initial results from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T therapy for relapsed/refractory multiple myeloma. The therapy demonstrated a 60% overall response rate (ORR) at the highest administered dose of 320M CAR+ cells, with all responding patients achieving minimal residual disease (MRD) negative status. Notably, there was no observed neurotoxicity or graft-vs-host disease (GvHD). Ongoing enrollment aims to optimize dosing and lymphodepletion, with further data to be presented at the upcoming ASH Annual Meeting.